{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:50:10Z","timestamp":1786719010664,"version":"build-2736575974"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asian J Androl"],"published-print":{"date-parts":[[2018]]},"DOI":"10.4103\/aja.aja_12_18","type":"journal-article","created":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T02:14:23Z","timestamp":1521166463000},"page":"215","source":"Crossref","is-referenced-by-count":12,"title":["Bone-targeted therapies to reduce skeletal morbidity in prostate cancer"],"prefix":"10.4103","volume":"20","author":[{"given":"TanyaB","family":"Dorff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1008-682X.227685-1","first-page":"1417\u201323","volume-title":"Interactions of human prostatic epithelial cells with bone marrow endothelium: binding and invasion","author":"Scott","year":"2001","journal-title":"Br J Cancer"},{"key":"key-10.4103\/1008-682X.227685-2","first-page":"2665\u201377","volume-title":"Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model","author":"Sudhan","year":"2016","journal-title":"Int J Cancer"},{"key":"key-10.4103\/1008-682X.227685-3","first-page":"92\u2013104","volume-title":"RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes","author":"Armstrong","year":"2008","journal-title":"Prostate"},{"key":"key-10.4103\/1008-682X.227685-4","first-page":"657\u201364","volume-title":"Integrins in prostate cancer progression","author":"Goel","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"key-10.4103\/1008-682X.227685-5","first-page":"749\u201357","volume-title":"Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735.A study by the DOD\/PCF prostate cancer clinical trials consortium","author":"Alva","year":"2012","journal-title":"Invest New Drugs"},{"key":"key-10.4103\/1008-682X.227685-6","first-page":"674\u20139","volume-title":"A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human \u03b1(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer","author":"Chu","year":"2011","journal-title":"Invest New Drugs"},{"key":"key-10.4103\/1008-682X.227685-7","first-page":"7851\u201360","volume-title":"Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion","author":"McNeel","year":"2005","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1008-682X.227685-8","first-page":"337\u201342","volume-title":"Osteoclast differentiation and activation","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"key-10.4103\/1008-682X.227685-9","first-page":"17\u201325","volume-title":"Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastases","author":"Nemeth","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"key-10.4103\/1008-682X.227685-10","first-page":"289\u201398","volume-title":"Expression of RANKL\/RANK\/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation","author":"Chen","year":"2006","journal-title":"Cancer"},{"key":"key-10.4103\/1008-682X.227685-11","first-page":"401\u20139","volume-title":"Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab","author":"Lacey","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"key-10.4103\/1008-682X.227685-12","first-page":"373\u201386","volume-title":"Bone metastasis: the importance of the neighbourhood","author":"Croucher","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"key-10.4103\/1008-682X.227685-13","first-page":"2151\u20138","volume-title":"Tumor-induced pressure in the bone microenvironment causes osteoctyes to promote the growth of prostate cancer bone metastases","author":"Sottnik","year":"2015","journal-title":"Cancer Res"},{"key":"key-10.4103\/1008-682X.227685-14","first-page":"247\u201356","volume-title":"Prostate cancer derived acid phosphatase promotes an osteoblastic response in the bone microenvironment","author":"Larson","year":"2014","journal-title":"Clin Exp Metastasis"},{"key":"key-10.4103\/1008-682X.227685-15","first-page":"10954\u20139","volume-title":"A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases","author":"Yin","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key-10.4103\/1008-682X.227685-16","first-page":"1567","volume-title":"Abstract 1567: Prostate cancer-derived exosomes alter the metabolic microenvironment of bone marrow pre-metastatic niche through PKM2 to promote bone metastasis","author":"Dai","year":"2016","journal-title":"Cancer Res"},{"key":"key-10.4103\/1008-682X.227685-17","first-page":"189\u201398","volume-title":"Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment","author":"Eaton","year":"2003","journal-title":"Cancer Treat Rev"},{"key":"key-10.4103\/1008-682X.227685-18","first-page":"1240\u20137","volume-title":"Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases","author":"Berruti","year":"1999","journal-title":"Clin Chem"},{"key":"key-10.4103\/1008-682X.227685-19","first-page":"1458\u201368","volume-title":"A randomized, placebo- controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"key-10.4103\/1008-682X.227685-20","first-page":"1537\u201342","volume-title":"Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer","author":"Reed","year":"2004","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.227685-21","first-page":"1228\u201336","volume-title":"Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases","author":"Chen","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"key-10.4103\/1008-682X.227685-22","first-page":"4925\u201335","volume-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","author":"Coleman","year":"2005","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.227685-23","first-page":"906\u201312","volume-title":"Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial","author":"Hortobagyi","year":"2017","journal-title":"JAMA"},{"key":"key-10.4103\/1008-682X.227685-24","first-page":"48\u201358","volume-title":"Effect of longer-interval vs.standard dosing of zoledronic acid on skeletal events in patients with bone metastases","author":"Himelstein","year":"2017","journal-title":"JAMA"},{"key":"key-10.4103\/1008-682X.227685-25","first-page":"35\u201344","volume-title":"Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment","author":"Mundy","year":"2001","journal-title":"Semin Oncol"},{"key":"key-10.4103\/1008-682X.227685-26","first-page":"1143\u201350","volume-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (Alliance)","author":"Smith","year":"2014","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.227685-27","first-page":"19\u201325","volume-title":"Addition of docetaxel, zoledronic acid, or both to long term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage platform randomized controlled trial","author":"James","year":"2016","journal-title":"Lancet"},{"key":"key-10.4103\/1008-682X.227685-28","first-page":"5\u201325","volume-title":"Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: a systematic review within the European Association for Palliative Care guidelines project","author":"Porta-Sales","year":"2017","journal-title":"Palliat Med"},{"key":"key-10.4103\/1008-682X.227685-29","first-page":"813\u201322","volume-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"key-10.4103\/1008-682X.227685-30","first-page":"39\u201346","volume-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomized, placebo-controlled trial","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"key-10.4103\/1008-682X.227685-31","first-page":"3800\u20136","volume-title":"Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analysis by baseline PSA doubling time","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.227685-32","first-page":"745\u201355","volume-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1008-682X.227685-33","first-page":"1063\u20139","volume-title":"New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin a receptor blockade","author":"Nelson","year":"1999","journal-title":"Urology"},{"key":"key-10.4103\/1008-682X.227685-34","first-page":"1143\u20139","volume-title":"Suppression of prostate cancer induced bone remodeling by the endothelin receptor a antagonist atrasentan","author":"Nelson","year":"2003","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.227685-35","first-page":"1959\u201366","volume-title":"A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer","author":"Carducci","year":"2007","journal-title":"Cancer"},{"key":"key-10.4103\/1008-682X.227685-36","first-page":"893\u2013900","volume-title":"Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomized phase 3 trial","author":"Quinn","year":"2013","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/1008-682X.227685-37","first-page":"5709\u201318","volume-title":"Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone","author":"Nelson","year":"2012","journal-title":"Cancer"},{"key":"key-10.4103\/1008-682X.227685-38","first-page":"1740\u20137","volume-title":"Phase III, randomized placebo controlled study of docetaxel in combination with zibotentan in patients with metastatic castration- resistant prostate cancer","author":"Fizazi","year":"2013","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.227685-39","first-page":"187\u201392","volume-title":"Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer","author":"Miller","year":"2013","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"key-10.4103\/1008-682X.227685-40","first-page":"67\u201378","volume-title":"Latent bone metastasis in breast cancer tied to Src-dependent survival signals","author":"Zhang","year":"2009","journal-title":"Cancer Cell"},{"key":"key-10.4103\/1008-682X.227685-41","first-page":"179\u201384","volume-title":"A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study","author":"Lara","year":"2009","journal-title":"Anticancer Drugs"},{"key":"key-10.4103\/1008-682X.227685-42","first-page":"7421\u20138","volume-title":"Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer","author":"Yu","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1008-682X.227685-43","first-page":"1307\u201316","volume-title":"Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomized double-blind phase 3 trial","author":"Araujo","year":"2013","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/1008-682X.227685-44","first-page":"abstr 167","volume-title":"Abiraterone plus prednisone alone or with dasatinib in chemotherapy-na\u00efve metastatic castration resistant prostate cancer","author":"Dorff","year":"2017","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.227685-45","first-page":"1113\u20137","volume-title":"High expression of the Met receptor in prostate cancer metastasis to bone","author":"Knudsen","year":"2002","journal-title":"Urology"},{"key":"key-10.4103\/1008-682X.227685-46","first-page":"412\u201319","volume-title":"Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.227685-47","first-page":"3005\u201313","volume-title":"Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1","author":"Smith","year":"2016","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.227685-48","first-page":"213\u201323","volume-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","author":"Parker","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Asian Journal of Andrology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:42:41Z","timestamp":1786714961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aja.aja_12_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"alternative-id":["227685"],"URL":"https:\/\/doi.org\/10.4103\/aja.aja_12_18","relation":{},"ISSN":["1008-682X"],"issn-type":[{"value":"1008-682X","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}